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Abstract
Background: Gout frequently affects the foot yet relatively little is known about the effects of gout on foot
structure, pain and functional ability. This study aimed to describe the impact of gout in a UK primary care
population.
Methods: A cross-sectional study was nested within an observational cohort study of adults aged ≥50 years
with foot pain. Participants with gout were identified through their primary care medical records and each
matched on age (±2 years) and gender to four participants without gout. Differences in person-level variables
(SF-12 Physical Component Score, Manchester Foot Pain and Disability Index and Short Physical Performance
Battery) between gout and non-gout participants were determined using regression models. Differences in
foot-level variables (pain regions, skin lesions, deformities, foot posture, and non-weightbearing range of
motion) were determined using multi-level regression models. All models were adjusted for body mass index.
Means and probabilities with 95% confidence intervals were calculated.
Results: Twenty-six participants with gout were compared to 102 participants without gout (77% male; mean
age 66 years, standard deviation 11). Subtalar joint inversion and eversion and 1st metatarsophalangeal joint
(MTPJ) dorsiflexion range of motion were significantly lower in the gout participants compared to the non-
gout participants. Gout participants were more likely to have mallet toes and less likely to have claw toes
compared to non-gout participants. There were no statistically significant differences in person-level variables,
foot posture, ankle dorsiflexion range of motion, hallux valgus, pain regions, or skin lesions.
Conclusions: Non-weightbearing range of motion at the subtalar joint and 1st MTPJ was reduced in people
with gout. Patients with gout who present with chronic foot problems should therefore undergo appropriate
clinical assessment of foot structure.
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Background
Gout is the most common inflammatory arthritis, af-
fecting 2.5% of the UK population [1]. The causal risk
factor is hyperuricaemia, leading to the formation of
monosodium urate (MSU) crystals in and around the
joints, which may result in severely painful acute at-
tacks and a chronic arthropathy. Gout is most com-
mon in the small joints, with 43–76% of first
episodes occurring in the first metatarsophalangeal
joint (MTPJ), but also commonly affects the midfoot
and ankle joints [2, 3].
Whilst the predilection of attacks of gout for the
foot and ankle is well-recognised, the chronic effects
of MSU crystal deposition on foot structure and
function have been under-researched. Four small
cross-sectional studies performed in New Zealand re-
cruited adults with chronic gout from rheumatology
clinics and found higher levels of foot-related pain
and disability, reduced peak ankle joint angular vel-
ocity and slower walking speed with shorter step and
stride lengths, reduced range of motion in the 1st
MTPJ dorsiflexion, lower peak plantar pressures in
the hallux and had higher pressure time integrals in
the midfoot compared to participants without gout
[4–7]. Reduced foot and ankle muscle strength in
gout has also been demonstrated [8]. However, the
generalisability of these findings and whether they can
be reproduced in a primary care gout population
where disease severity is likely to be milder is
unknown.
Therefore, the aim of this study was to describe the ef-
fect of gout on the functional and biomechanical charac-
teristics of the foot in a UK primary care population.
Methods
The Clinical Assessment Study of the Foot (CASF) is a
prospective longitudinal cohort study. Adults aged ≥50
years registered at one of four general practices in North
Staffordshire, UK were mailed a self-report health survey
questionnaire. This questionnaire comprised of 5 main
sections: (i) general health; (ii) specific health problems
including musculoskeletal co-morbidity and pain; (iii)
the presence, duration, location, severity, and impact of
foot pain; (iv) demographic and socioeconomic charac-
teristics; and (v) employment. Non-responders were sent
reminders after 2 and 4 weeks [9]. Respondents who had
indicated they experienced foot pain in the last 12
months and consented to further contact were sent an
invitation to attend a research clinic as well as a Partici-
pant Information Sheet [9].
At the research clinic, the clinical assessment con-
sisted of a standardised clinical interview and physical
examination performed by a clinical assessor. This as-
sessment lasted approximately two hours and involved a
physical examination of the feet and simple anthropo-
metric measurements [9].
For this nested analysis, clinic attenders with inflam-
matory arthritis (rheumatoid arthritis, psoriatic arthritis,
or non-specific inflammatory arthritis) identified
through their medical records or study radiographs, or
those who did not consent to primary care medical rec-
ord review, or had missing body mass index (BMI) were
excluded.
Participants with gout were identified by searching
their primary care medical records during the period
from 18months prior to the clinical assessment to 18
months afterwards for specific Read codes for gout. Indi-
viduals without a Read code (in the system used across
UK general practices, which codes standardised clinical
terminology) for gout but who had “gout” mentioned in
their consultation free-text were also included if there
was mention of a gout attack and/or clinical features (se-
vere pain and inflammation in the joint) consistent with
that of gout. The gout participants were then matched
on age (±2 years) and gender to four non-gout partici-
pants. Participants that could not be matched were
excluded.
Variables
Sixteen variables were chosen from the health survey
questionnaire and clinical assessment.
Participant characteristics
Participant characteristics used to describe the study
sample were socio-economic status based on current or
previous occupation; age; gender; any foot pain or ache
in the last month, and BMI measured at the clinical
assessment.
Person-level variables
Variables collected at the person-level were:
i) Physical component score (PCS): calculated using
12 physical component responses from a 36-item
health survey, with higher scores indicating better
physical function [10].
ii) Foot function and foot pain: calculated from the
Manchester Foot Pain and Disability Index
(MFPDI) function and pain subscales [9]. It has
been shown the function and pain subscales fit the
Rasch model thus their transformed scores were
used, with higher scores indicating worse function
and pain respectively [11].
iii) Short Physical Performance Battery (SPPB):
participants were observed performing a series of
tests; standing balance test (based on the held
side by side stand for 10 s, held semi-tandem
stand for 10 s, and held full tandem stand for less
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than 2 s; 3–9 s and 10 s), time taken to rise from a
chair 5 times, and gait speed test (fastest of two timed
walks of an 8-ft course at the participants usual
walking speed). These were scored individually, and
each participant was given an overall SPPB score,
with higher scores indicating better lower extremity
function [12].
Foot level variables: The foot-level variables that were
collected in both the left and right feet were:
iv) Hallux valgus: participants were asked to indicate
the severity of hallux valgus in each foot using five
validated line drawings, increasing in 15°
increments. Those selecting one of the three most
severe categories in each foot were classed as
having hallux valgus [13].
v) Pain regions: participants were asked if they
experienced any foot pain or ache lasting more than
a day in the last month; if they answered yes, they
were then asked to shade a foot manikin, indicating
the pain location in their feet. This information was
then categorised using a pre-defined marking
template [14].
vi) Foot posture index: consisted of a six-item
assessment of foot posture, with each item scored
between − 2 to + 2, which was then transformed
into a single score using Rasch analysis, with
lower scores indicating a more supinated foot
position and higher scores indicating a more
pronated position [15].
vii) Arch index: calculated from ratios of the middle
third area to the whole foot area (excluding the
toes) ascertained from carbon footprints taken in
relaxed bipedal standing [16, 17].
viii) Navicular height: measured in millimetres with a
ruler from the floor to the navicular tuberosity
with the participant in relaxed bipedal standing,
then normalised for foot size by dividing by foot
length [17, 18].
ix) Deformity: assessed on physical examination, the
palpable presence or absence of deformities on all
toes, 1st MTPJ, and lesser toes. MTPJ and
interphalangeal joint hyperextension were examined
at the 1st MTPJ. For the lesser toes, the type of
deformity examined were mallet, hammer, claw and
retracted toes [19].
x) Skin lesions: assessed by observation (both plantar
and dorsal) of each region of the foot (midfoot,
greater toe, and lesser toes) for hyperkeratotic
lesions and ulcers.
xi) First MTPJ dorsiflexion non-weightbearing range
of motion: measured in degrees using a
goniometer, looking at the maximum passive
hallux extension with no weight bearing and the
ankle relaxed [20].
xii) Subtalar joint non-weightbearing range of
motion eversion/inversion: a standardised
assessment measuring the participant’s subtalar
joint eversion and inversion in degrees using a
goniometer [21].
xiii) Ankle dorsiflexion non-weightbearing range of
motion with the knee flexed/extended: measured in
degrees with an inclinometer during a weight-
bearing lunge test [22].
Confounding variables were considered to be age, gen-
der, and BMI [23].
Statistical analysis
Participant characteristics were described between gout
and non-gout participants using appropriate statistics;
for continuous variables, the mean and standard devi-
ation and a p-value testing for differences between
groups via the F-test were reported; for categorical vari-
ables, the frequency and percentages and a p-value test-
ing for differences between groups via the Chi-square
test were reported.
Person-level variables were compared between gout and
non-gout participants using regression models. For con-
tinuous variables, linear regression was used and the mean
and 95% confidence interval (CI) was reported and signifi-
cance between the two groups was determined via the
F-test. Although the SPPB was treated as a continuous
measure, a ceiling effect was present hence tobit regres-
sion was used. For binary and ordinal variables, logistic or
ordinal regression was used and the probability of having
an outcome and 95% CI for gout and non-gout partici-
pants were reported and significance between the two
groups was determined via the Chi-square test.
Foot-level variables were compared between gout and
non-gout participants using random intercept linear or
logistic multilevel regression models (as appropriate) to
take into account the lack of independence due to
clustering of feet belonging to a participant [24]. As
described above, results were reported as means or
probabilities with 95% CIs and p-values.
Although matching on age and gender removed
their confounding effects, this resulted in the loss of
independence between gout and non-gout participants
within a matched group. Therefore, the standard er-
rors were adjusted to take into account this clustering
in all analyses. All regression models were also ad-
justed for BMI.
All analyses were two-tailed and a p-value < 0.05 was
considered statistically significant. All analysis was
performed on STATA v14 (StataCorp, College Station,
TX, USA).
Petty et al. Journal of Foot and Ankle Research            (2019) 12:8 Page 3 of 9
Results
Of the 5109 responders to the health survey question-
naire, 560 participants attended the clinical assessment.
Of these 54 were excluded from this analysis, due to lack
of consent for medical record review (n = 28), inflamma-
tory arthritis (n = 24), or missing BMI (n = 2), leaving 506
for sampling. Twenty-six gout participants were identified
and then individually matched to four non-gout partici-
pants, although two gout participants could only be
matched to three non-gout participants each.
Ninety-eight (77%) participants were male and the
mean (standard deviation) age was 66.16 (10.77) years.
Characteristics of the gout and non-gout participants are
presented in Table 1. Age and gender were similar be-
tween the groups, indicating successful matching. Mean
BMI was similar in both groups. There were more over-
weight participants in the gout group than the non-gout
group, however this was not statistically significant.
There were no differences in pain, physical function or
lower extremity function between the gout and
non-gout participants (Table 2). The prevalence of skin
lesions, location of foot pain and deformities did not dif-
fer between the gout and non-gout participants in either
foot, with the exception of hallux valgus, which occurred
more frequently in the left foot in the non-gout partici-
pants, and mallet toe, which was observed more fre-
quently in the gout participants in the left foot (Table 3).
When combining foot-level variables from the left and
right feet (Table 4), the ranges of motion in the subtalar
joint inversion and eversion and 1st MTPJ dorsiflexion
were lower in the gout participants than the non-gout
participants. The probability of having a mallet toe was
higher in the gout participants, whereas the probability
of having a claw toe was slightly lower in the gout par-
ticipants compared to the non-gout participants.
Discussion
This study found that people with gout recruited from a UK
primary care population have reduced non-weightbearing
range of motion in the subtalar joint and the 1st MTPJ
compared to those without gout and were more likely to
have a mallet toe deformity. In contrast, people with gout
were less likely to have a claw toe deformity compared to
those without gout. No associations were found between
gout and physical function, skin lesions, hammer and
retracted toe deformities, or foot posture. There were no
consistent differences between gout and non-gout partici-
pants in foot pain location, including the 1st MTPJ and hal-
lux, and presence of hallux valgus.
Previous research on functional and biomechanical
characteristics of foot disease in participants com-
pared people with severe gout recruited from rheuma-
tology clinics to asymptomatic controls [4, 5]. This
differed to our study, where both gout and non-gout
Table 1 Participant characteristics
Participant characteristics Non-gout (n = 102) Gout (n = 26) P-value
Age (years): Mean (SD) 66.20 (10.75) 66.04 (11.07) 0.565
Sex: N (%)
Male 78 (76.47) 20 (76.92) 0.149
Female 24 (23.53) 6 (23.08)
BMI (kg/m2): Mean (SD) 29.11 (4.71) 30.46 (4.43) 0.176
BMI categories: N (%)
Normal weight < 25 kg/m2 20 (19.61) 0 (0.00) 0.207
Overweight 25–30 kg/m2 44 (43.14) 16 (61.54)
Obese ≥30 kg/m2 38 (37.25) 10 (38.46)
Any ache or pain in the feet in the last month: N (%)
Yes 89 (87.25) 20 (76.92) 0.256
Socio-economic status: N (%)
Higher managerial, administrative and professional 24 (25.53) 4 (16.67) 0.797
Intermediate 15 (15.96) 8 (33.33)
Routine and manual 55 (58.51) 12 (50.00)
Ethnicity: N (%)
White UK/European 97 (97.00) 26 (100.00) 0.371
Afro Caribbean/Asian/African 3 (3.00) 0 (0.00)
Allopurinol prescription: N (%)
Yes – 12 (46.15) –
BMI Body Mass Index, N Number of participants, SD Standard Deviation
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participants aged ≥50 years had reported foot pain in
the last 12months and were recruited from primary care.
As gout tends to present itself after the third decade of
life, it is possible participants have had gout for a number
of years. It seems likely that the differences between our
findings and those of these previous studies could have
arisen from our gout cases having less severe gout (which
seems likely in a population recruited from primary care
compared with a specialist clinic) and/or our non-gout
participants also having foot-related problems. It is there-
fore noteworthy that despite these differences, people with
gout in our study had reduced non-weightbearing range
of motion at the 1st MTPJ and subtalar joint. This finding
is similar to a previous study which found a larger reduced
range of motion by 17.9° (compared to 8.7° in our study)
at the 1st MTPJ in gout compared to non-gout partici-
pants [7]. We did not, however, replicate certain findings
of previous studies [4, 5] that showed that walking speed
was significantly slower for gout participants than
non-gout participants. This may be due to both gout and
non-gout participants having foot pain which is known to
have a mediating effect on walking speed [25]. However,
the methods used to assess walking speed in our study
and other published studies differ, requiring caution when
comparing findings of these studies. A previous study [4]
and a systematic review [2] also found participants with
gout reported higher levels of pain and foot disability than
those without gout. In our study, participants with gout
reported higher pain levels and foot disability, although
this was not statistically significant.
The causes of limited 1st MTPJ and subtalar range of
motion are unknown. Both joints are affected by gout and
hence it is possible that features of gout such as synovial
inflammation or tophus could play a role [7, 26, 27]. A
possible alternative explanation for limited range of mo-
tion is OA [5], although non-traumatic OA of the subtalar
joint is uncommon. First MTPJ OA is common in people
with gout [3]. We could not explore these possibilities in
the current study and further research is warranted.
The absence of any differences in foot posture measures
between the groups may be explained by previous obser-
vations suggesting that the flexor tendons and plantar
fascia are rarely affected by gout [28]. However, previous
studies using dynamic plantar pressure measurements
Table 2 Differences in person-level variables between gout and non-gout participants adjusted for BMI
Variables Non-gout
N = 102
Gout
N = 26
P value
MFPDI pain score: mean (95% CI) 0.02 (−0.27, 0.30) −0.45 (−1.27, 0.37) 0.272
MFPDI function score: mean (95% CI) −0.63 (− 0.95, − 0.30) −0.50 (− 1.41, 0.41) 0.791
SPPB: mean (95% CI) 8.08 (7.29, 8.87) 8.57 (7.08, 10.05) 0.434
PCS: mean (95% CI) 36.50 (34.07, 38.93) 38.87 (33.91, 43.82) 0.343
Side by side stand test: N, probability (95% CI) 100, 0.99 (0.97, 1.01) 25, 0.95 (0.87, 1.04) 0.224
Semi-tandem stand test: N, probability (95% CI) 91, 0.90 (0.84, 0.97) 21, 0.80 (0.64, 0.96) 0.069
Full tandem stand test: N, probability (95% CI)
Unable to complete or held for < 2 s 22, 0.23 (0.12, 0.34) 6, 0.20 (0.04, 0.36) 0.726
Held for 3–9 s 10, 0.09 (0.04, 0.14) 1, 0.08 (0.03, 0.13)
Held for 10 s 69, 0.69 (0.57, 0.80) 19, 0.72 (0.54, 0.91)
Standing balance ability: N, probability (95% CI)
0 (poor) 1, 0.02 (0.00, 0.04) 1, 0.02 (0.00, 0.04) 0.910
1 9, 0.10 (0.04, 0.16) 4, 0.10 (0.00, 0.21)
2 12, 0.10 (0.04, 0.16) 1, 0.10 (0.03, 0.17)
3 10, 0.09 (0.03, 0.14) 1, 0.08 (0.03, 0.14)
4 (good) 69, 0.69 (0.58, 0.80) 19, 0.70 (0.50, 0.91)
Time taken to rise from a chair 5 times (seconds): N, probability (95% CI)
Unable to complete 15, 0.14 (0.08, 0.20) 2, 0.11 (0.05, 0.18) 0.454
Slowest risers (15.3, 55.5) 25, 0.24 (0.16, 0.32) 5, 0.21 (0.12, 0.31)
2nd slowest risers (11.9, 15.2) 19, 0.21 (0.16, 0.26) 7, 0.20 (0.15, 0.25)
2nd fastest risers (9.3, 11.8) 19, 0.19 (0.12, 0.25) 5, 0.20 (0.13, 0.27)
Fastest risers (4.1, 9.2) 24, 0.23 (0.13, 0.32) 6, 0.27 (0.13, 0.42)
Gait speed (seconds): mean (95% CI) 7.24 (5.54, 8.95) 5.81 (2.55, 9.07) 0.436
BMI Body Mass Index, CI Confidence Interval, MFPDI Manchester Foot Pain and Disability Index, N Number of participants, PCS Physical Component Score, SPPB
Short Physical Performance Battery
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suggest that the foot may function in a more pronated
position during walking, as evidenced by increased pres-
sure in the midfoot in people with gout [5]. As we did not
measure plantar pressures in our study, we were unable to
confirm this in our cohort. There is also the possibility
that foot posture index may not have been accurately cap-
tured as people could adjust their foot position to offload
pain [29]. In people with gout, tophus deposition may sig-
nificantly alter foot alignment [29].
People with gout were less likely to have hallux valgus
in the left foot, which is inconsistent with a previous pri-
mary care-based study where hallux valgus was more
prevalent in age- and gender-matched control subjects
without gout [7, 30]. This could be because the control
group in our study included individuals experiencing
foot pain, whereas the control group in the previous
study [30] were individuals over 30 registered in two
general practices. However, there is no pathophysio-
logical reason to expect hallux valgus to preferentially
affect the left foot less commonly than the right in
people with gout, and this association disappeared when
examining hallux valgus across both feet, suggesting a
possible spurious finding.
A strength of this study is its primary care setting, en-
suring its generalisability and relevance to the majority
of people with gout in the UK who are treated entirely
Table 3 Foot deformity, pain and skin lesions. Values are N (%)
Left foot P value Right foot P value
Non-gout
N = 102
Gout
N = 26
Non-gout
N = 102
Gout
N = 26
Plantar aspect skin lesion
Midfoot 51 (50.00) 11 (42.31) 0.553 52 (50.98) 11 (42.31) 0.470
Whole Foot 75 (73.53) 16 (61.54) 0.291 75 (73.53) 17 (65.38) 0.448
Greater toe 57 (55.88) 13 (50.00) 0.577 65 (63.73) 13 (50.00) 0.250
Lesser toes 60 (58.82) 11 (42.31) 0.203 57 (55.88) 11 (42.31) 0.262
Dorsal aspect skin lesion
Midfoot 3 (2.94) 0 (0.00) – 6 (5.88) 0 (0.00) –
Whole Foot 45 (44.12) 7 (26.92) 0.136 47 (46.08) 7 (26.92) 0.097
Greater toe 24 (23.53) 2 (7.69) 0.083 26 (25.49) 3 (11.54) 0.133
Lesser toes 35 (34.31) 6 (23.08) 0.270 35 (34.31) 6 (23.08) 0.290
Pain regions
1st MTPJ 39 (38.24) 10 (38.46) 0.983 41 (40.20) 10 (38.46) 0.864
Hallux 34 (33.33) 6 (23.08) 0.353 32 (31.37) 11 (42.31) 0.339
Greater toe 50 (49.02) 11 (42.31) 0.541 49 (48.04) 14 (53.85) 0.584
Lesser toes 47 (46.08) 9 (34.62) 0.324 48 (47.06) 9 (34.62) 0.292
Plantar forefoot 32 (31.37) 6 (23.08) 0.433 30 (29.41) 7 (26.92) 0.796
Midfoot 46 (45.10) 12 (46.15) 0.919 47 (46.08) 8 (30.77) 0.216
Medial arch 26 (25.49) 8 (30.77) 0.597 23 (22.55) 5 (19.23) 0.743
Ankle 37 (36.27) 12 (46.15) 0.294 37 (36.27) 8 (30.77) 0.575
Plantar heel 15 (14.71) 5 (19.23) 0.616 17 (16.67) 4 (15.38) 0.887
Hallux valgus 29 (28.43) 1 (3.85) 0.024 31 (30.39) 7 (26.92) 0.745
Deformity
All toes 61 (59.80) 18 (69.23) 0.420 64 (62.75) 14 (53.85) 0.392
1st MTPJ 10 (9.80) 1 (3.85) 0.377 9 (8.82) 3 (11.54) 0.696
Lesser toes 59 (57.84) 18 (69.23) 0.331 62 (60.78) 14 (53.85) 0.527
Type of deformity for lesser toes
Hammer 35 (34.31) 10 (38.46) 0.675 31 (30.39) 8 (30.77) 0.966
Mallet 10 (9.80) 10 (38.46) < 0.001 18 (17.65) 7 (26.92) 0.316
Claw 24 (23.53) 3 (11.54) 0.194 23 (22.55) 3 (11.54) 0.218
Retracted 7 (6.86) 1 (3.85) 0.598 6 (5.88) 1 (3.85) 0.705
MTPJ Metatarsophalangeal joint, N Number of participants
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in primary care. There are, however, several limitations
which merit acknowledgement. Firstly, due to this study
being a secondary analysis of data, the number of gout
participants was limited, hence reducing statistical power
to detect statistically significant differences between the
gout and non-gout participants. Considering the large
number of variables assessed for differences between
gout and non-gout participants, type 2 errors were more
likely to occur. However, multi-level regression analysis
was performed to account for variables measured for
both feet of patients, which increased the power of ana-
lysis as opposed to using only one foot as is the case
Table 4 Multilevel regression modelling to account for correlation between feet adjusting for BMI
Variables Non-gout
N = 102
Gout
N = 26
P value
Arch index: mean (95% CI) 0.24 (0.23, 0.25) 0.24 (0.22, 0.25) 0.636
Subtalar joint inversion ROM: mean (95% CI) 26.71 (25.09, 28.34) 21.15 (18.23, 24.06) < 0.001
Subtalar joint eversion ROM: mean (95% CI) 12.12 (11.09, 13.16) 10.00 (8.47, 11.52) 0.010
First MTPJ dorsiflexion ROM: mean (95% CI) 63.09 (59.56, 66.62) 54.42 (47.81, 61.02) 0.035
Ankle dorsiflexion knee extended ROM: mean (95% CI) 61.94 (60.45, 63.42) 62.90 (59.43, 66.37) 0.609
Ankle dorsiflexion knee flexed ROM: mean (95% CI) 51.97 (50.32, 53.63) 55.03 (51.64, 58.42) 0.092
Navicular height: mean (95% CI) 0.18 (0.17, 0.18) 0.17 (0.16, 0.19) 0.922
Foot posture index: mean (95% CI) 2.29 (1.95, 2.64) 2.20 (1.61, 2.79) 0.791
Hallux valgus: probability (95% CI) 0.29 (0.19, 0.39) 0.17 (0.07, 0.27) 0.065
Foot pain regions
MTPJ: probability (95% CI) 0.39 (0.30, 0.49) 0.38 (0.22, 0.53) 0.831
Hallux: probability (95% CI) 0.32 (0.23, 0.40) 0.32 (0.15, 0.49) 0.987
Greater toes: probability (95% CI) 0.49 (0.39, 0.59) 0.47 (0.31, 0.64) 0.900
Lesser toes: probability (95% CI) 0.47 (0.37, 0.57) 0.33 (0.18, 0.48) 0.149
Plantar forefoot: probability (95% CI) 0.30 (0.20, 0.41) 0.24 (0.12, 0.36) 0.397
Midfoot: probability (95% CI) 0.46 (0.37, 0.54) 0.38 (0.22, 0.54) 0.378
Medial arch: probability (95% CI) 0.24 (0.17, 0.30) 0.25 (0.12, 0.37) 0.901
Ankle pain: probability (95% CI) 0.37 (0.28, 0.45) 0.37 (0.21, 0.54) 0.935
Plantar heel: probability (95% CI) 0.16 (0.13, 0.20) 0.17 (0.14, 0.20) 0.708
Deformity
1st MTPJ: probability (95% CI) 0.10 (0.04, 0.15) 0.09 (0.00, 0.19) 0.963
All toes: probability (95% CI) 0.62 (0.38, 0.86) 0.64 (0.33, 0.96) 0.898
Lesser toes: probability (95% CI) 0.59 (0.46, 0.72) 0.63 (0.40, 0.86) 0.754
Type of deformity for lesser toes
Mallet: probability (95% CI) 0.14 (0.09, 0.19) 0.33 (0.15, 0.51) 0.017
Hammer: probability (95% CI) 0.30 (0.17, 0.44) 0.34 (0.09, 0.59) 0.760
Claw: probability (95% CI) 0.18 (0.17, 0.18) 0.17 (0.17, 0.18) 0.041
Retracted: probability (95% CI) 0.06 (0.00, 0.23) 0.05 (0.00, 0.20) 0.927
Plantar aspect skin lesion
Whole foot: probability (95% CI) 0.74 (0.67, 0.81) 0.65 (0.46, 0.85) 0.350
Greater toe: probability (95% CI) 0.59 (0.51, 0.68) 0.52 (0.34, 0.70) 0.472
Lesser toes: probability (95% CI) 0.57 (0.47, 0.67) 0.43 (0.24, 0.63) 0.275
Midfoot: probability (95% CI) 0.51 (0.41, 0.60) 0.42 (0.21, 0.62) 0.493
Dorsal aspect skin lesion
Whole foot: probability (95% CI) 0.39 (0.00, 0.89) 0.23 (0.00, 1.10) 0.780
Greater toe: probability (95% CI) 0.24 (0.16, 0.31) 0.11 (0.00, 0.23) 0.100
Lesser toes: probability (95% CI) 0.38 (0.22, 0.54) 0.20 (0.08, 0.31) 0.115
BMI Body Mass Index, CI Confidence Interval, MTPJ Metatarsophalangeal joint, N Number of participants, ROM range of motion
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with most other studies. Also, missing data was not an
issue with the largest proportion of missing data being
6% for an outcome. Secondly, although the diagnostic
gold standard for gout is MSU crystal identification in
synovial fluid [31], this is not often performed in primary
care, risking misclassification bias. Previous studies,
however, have shown that GP diagnosis is reliable [32,
33] with the positive predictive value of a recorded diag-
nosis of gout in UK medical records being 90% [32].
New classification criteria have been published by ACR/
EULAR [34], however publication took place after we
completed data collection for this study. Finally, the in-
ability to distinguish which foot was affected by gout
limits our ability to investigate the relationship between
foot characteristics and the involvement of gout specific-
ally in that foot. All the participants within this study
had a history of foot pain, meaning associations between
gout and foot characteristics may have been masked. Fi-
nally, because this was a nested secondary analysis, clin-
ical characteristics of gout were not available, so we
were unable to describe the severity of the gout cases or
investigate the effect of severity on the associations
observed.
Conclusions
People with gout demonstrated reduced range of subtalar
joint and 1st MTPJ motion compared to those without
gout and were more likely to have mallet toe deformities.
Further longitudinal large-scale research studies are re-
quired to confirm if gout is the cause of these findings and
establish how they should be managed. Clinicians should
be aware of the impact of gout on non-weightbearing
range of motion and undertake appropriate assessment in
patients with gout presenting with chronic foot problems.
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